Key result
Ranolazine is proposed to reduce ischemia-induced diastolic dysfunction by reducing the late sodium current, decreasing sodium entry, and indirectly reducing calcium uptake.
Why the study?
Does ranolazine reduce ischemia-induced diastolic dysfunction in ischemic myocardium?
Does ranolazine reduce ischemia-induced diastolic dysfunction in ischemic myocardium?
Ranolazine's anti-ischemic effects are mediated by the reduction of late sodium current, which prevents calcium overload and improves diastolic relaxation.
Answers are grounded in this paper and cite their sources.
Mechanism supports ranolazine for ischemic diastolic dysfunction; hypothesis-generating and requires prospective trials before any clinical use.
Ischaemia of myocardium is associated with increases in the late sodium current (INa), intracellular sodium and calcium concentrations, calcium overload, and impairment of contractile relaxation (i.e. increased diastolic wall tension). An increase in diastolic wall tension compresses the vasculature and reduces nutritive blood flow, creating a positive feedback system that further impairs myocardial oxygenation and contractile function. Ranolazine reduces the late INa and, is expected to decrease sodium entry into ischaemic myocardial cells. As a consequence, ranolazine is proposed to reduce calcium uptake indirectly via the sodium/calcium exchanger and to preserve ionic homeostasis and reverse ischaemia-induced contractile dysfunction.
No takes yet. Share an insight, caveat, or question.
Belardinelli et al. (2006) conducted a review in Ischemia-induced diastolic dysfunction. Ranolazine was evaluated. Ranolazine is proposed to reduce ischemia-induced diastolic dysfunction by reducing the late sodium current, decreasing sodium entry, and indirectly reducing calcium uptake.
Synapse has enriched 10 related papers. Consider them for comparative context: